Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06296251 · ClinicalTrials.gov registry record · NA
Dietary Supplementation on Body Fat Composition
A NA study of PreDiabetes and Dyslipidemias, sponsored by Brightseed.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT06296251: Recruiting NA study of PreDiabetes and Dyslipidemias, sponsored by Brightseed.
NCT06296251 is a NA study of PreDiabetes and Dyslipidemias that is actively recruiting participants, run by Brightseed. The registered enrollment target is 150 participants, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06296251, a NA study of PreDiabetes and Dyslipidemias, is actively recruiting participants, sponsored by Brightseed.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the current study is to examine the effects of a dietary supplement containing plant derived phenolics at two different dose levels in otherwise generally healthy adults with risk factors (high BMI at dyslipidemia and/or pre-diabetes) for body fat composition. The primary hypothesis is that supplementation with plant derived phenolics will decrease body fat composition compared to placebo.
Conditions Studied
Interventions
- OTHER Placebo treatment
- DIETARY_SUPPLEMENT Plant derived phenolics
Study Locations (1)
Illinois
- Biofortis Research - Addison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-04-18 |
| Est. Completion | 2025-02-27 |
| Phase | NA |
What NCT06296251 shows while recruiting
NCT06296251 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with PreDiabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo treatment is the first listed.
NCT06296251 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06296251 about?
NCT06296251 is a clinical study titled "Dietary Supplementation on Body Fat Composition". The purpose of the current study is to examine the effects of a dietary supplement containing plant derived phenolics at two different dose levels in otherwise generally healthy adults with risk factors (high BMI at dyslipidemia and/or pre-diabetes) for body fat composition. The primary hypothesis i...
What is the current status of trial NCT06296251?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2024-04-18. Estimated completion is 2025-02-27.
What conditions does trial NCT06296251 study?
This clinical trial studies the following conditions: PreDiabetes, Dyslipidemias.
What interventions are being tested in trial NCT06296251?
The interventions under investigation include: Placebo treatment (OTHER), Plant derived phenolics (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06296251?
This trial is sponsored by Brightseed, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06296251 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PreDiabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06296251's enrollment target sits among peer trials
150 49th of 149 higher than 100 of 149 other PreDiabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PreDiabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
RECRUITING · NA
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
-
Cleaner Air for Lower Cardiometabolic Risk
RECRUITING · NA
-
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI